There is experimental evidence that the WNT/β-catenin-pathway is able to up-regulate AR-mRNA expression in prostate cancer cell lines through interaction with TCF/LEF binding sites situated in the promoter region of the AR [41]. The gene discussed is AR; the disease is prostate cancer.